Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 4/20 | 0.47 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.38 |
| ▸ | MMP3 | P08254 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
| ▸ | HAT1 | O14929 | 1/20 | 0.35 |
| ▸ | EP300 | Q09472 | 1/20 | 0.35 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.35 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.35 |
| ▸ | FPR2 | P25090 | 1/20 | 0.35 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.35 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.35 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23461807 | 1.00 | CXCR2 (0.47) | CXCR2TRPV1MMP3EPHX2PPARG | |
| SCHEMBL25548967 | 0.91 | CXCR2 (0.46) | CXCR2TRPV1MMP3EPHX2PPARG | |
| SCHEMBL23460777 | 0.90 | CXCR2 (0.51) | CXCR2TRPV1EPHX2PPARGPPARA | |
| SCHEMBL23460779 | 0.90 | CXCR2 (0.51) | CXCR2TRPV1EPHX2PPARGPPARA | |
| SCHEMBL23461051 | 0.90 | CXCR2 (0.59) | CXCR2PPARG | |
| SCHEMBL38147033 | 0.90 | CXCR2 (0.59) | CXCR2PPARG | |
| SCHEMBL38147035 | 0.87 | CXCR2 (0.47) | CXCR2EPHX2NR1H4 | |
| SCHEMBL23460940 | 0.87 | CXCR2 (0.47) | CXCR2EPHX2NR1H4 | |
| SCHEMBL23460901 | 0.86 | CXCR2 (0.47) | CXCR2TRPV1EPHX2PPARGPPARA | |
| SCHEMBL23460914 | 0.83 | CXCR2 (0.49) | CXCR2TRPV1EPHX2PPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630498-B2 | Arylamides and methods of use thereof | GENZYME CORPORATION (US) | 2026-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630498-B2 | Arylamides and methods of use thereof | CFTR, CLIC1, CLCN2 | CXCR2 63/4885TRPV1 772/4885MMP3 3074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.